MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC

被引：6
|
作者：
Fang, Wenfeng [1 ]
Gan, Jiadi [1 ]
Hong, Shaodong [1 ]
Lu, Feng [2 ]
Zhang, Li [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
[2] Jinan Univ, Inst Life & Hlth Engn, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 07期
基金：
国家重点研发计划;
关键词：
CELL LUNG-CANCER; FUSION;
D O I：
10.1016/j.jtho.2019.02.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E148 / E151
页数：5
相关论文
共 50 条
  • [31] Identification of Novel ALK Rearrangement A2M-ALK in a Neonate with Fetal Lung Interstitial Tumor
    Onoda, Tadashi
    Kanno, Miyako
    Sato, Hiroko
    Takahashi, Noriyuki
    Izumino, Hiroko
    Ohta, Hiroshi
    Emura, Takaki
    Katoh, Hirohisa
    Ohizumi, Hiroyuki
    Ohtake, Hiroya
    Asao, Hironobu
    Dehner, Louis P.
    Hill, Ashley D.
    Hayasaka, Kiyoshi
    Mitsui, Tetsuo
    GENES CHROMOSOMES & CANCER, 2014, 53 (10): : 865 - 874
  • [32] Native and rearranged ALK copy number and rearranged ALK cell count in NSCLC: Implications for ALK inhibitor therapy.
    Camidge, D. Ross
    Skokan, Margaret
    Kiatsimkul, Porntip
    Helfrich, Barbara
    Schulte, Nathan
    Maxson, DeLee
    Aisner, Dara L.
    Franklin, Wilbur A.
    Doebele, Robert Charles
    Varella-Garcia, Marileila
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] A novel ALK rearrangement in an inflammatory myofibroblastic tumor in a neonate
    Owusu-Brackett, Nicci
    Johnson, Romaine
    Schindel, David T.
    Koduru, Prasad
    Cope-Yokoyama, Sandy
    CANCER GENETICS, 2013, 206 (9-10) : 353 - 356
  • [34] ALK plus advanced NSCLC New ALK Inhibitor extends Sequence Options
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (11) : 720 - 720
  • [35] Rare ALK Expression but no ALK Rearrangement in Pancreatic Ductal Adenocarcinoma and Neuroendocrine Tumors
    Graham, Rondell P. D.
    Oliveira, Andre M.
    Zhang, Lizhi
    PANCREAS, 2013, 42 (06) : 949 - 951
  • [36] INCIDENCE, OUTCOMES AND TOLERANCE IN EGFRM AND ALK-REARRANGEMENT POSITIVE NSCLC
    Whitmore, K.
    Sriram, K.
    Singh, M.
    RESPIROLOGY, 2019, 24 : 162 - 162
  • [37] Effectiveness of Alectinib in ALK Rearrangement NSCLC: Real World Data of Peru
    Roque, K.
    Galvez-Nino, M.
    Ruiz, R.
    Heredia, M.
    Castro-Mollo, M.
    Coanqui, O.
    Valdiviezo, N.
    Olivera, M.
    Andrade de Mello, R.
    Mas, L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S647 - S647
  • [38] RNA in situ detection and characterization of ALK rearrangement in NSCLC FFPE tissues
    Li, Na
    Wu, Shafei
    Wang, Mindy
    Sun, Hongzhe
    Zhang, Zhifu
    Park, Emily
    Ma, Xiao-Jun
    Zeng, Xuan
    Monroe, Robert
    CANCER RESEARCH, 2018, 78 (13)
  • [39] ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards
    Bestvina, Christine M.
    Vokes, Everett E.
    LANCET ONCOLOGY, 2017, 18 (12): : 1555 - 1556
  • [40] Verification and Implementation of the VENTANA Anti-ALK D5F3 Antibody in Detecting ALK Rearrangement in NSCLC
    Nadira, N.
    Al-Najjar, H.
    Higgins, C.
    Wallace, A.
    Harris, J.
    Bailey, S.
    Shelton, D.
    Thiryayi, S.
    Rana, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1950 - S1950
12345